# Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma

> **NCT04150562** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 2 (actual)

## Conditions studied

- Clear-Cell Renal Carcinoma

## Interventions

- **DRUG:** rhIL-15
- **BIOLOGICAL:** Avelumab

## Key facts

- **NCT ID:** NCT04150562
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-05-26
- **Primary completion:** 2021-07-23
- **Final completion:** 2021-09-16
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** This study was terminated early due to manufacturer withdrawal of support (study medication) due to lack of enrollment.
- **Last updated:** 2022-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04150562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04150562, "Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04150562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*